ETON
$22.32+1.55 (+7.46%)
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle...
Recent News
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
The mean of analysts' price targets for Eton Pharmaceuticals (ETON) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Eton Pharmaceuticals Inc (ETON) reports an 83% revenue increase and unveils promising new products, despite rising expenses and cash outflows.
Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Eton Pharmaceuticals, Inc.'s Q4 2025 earnings call
Eton Pharmaceuticals Q4 Earnings Call Highlights
Eton Pharmaceuticals (NASDAQ:ETON) reported fourth quarter 2025 product revenue of $21.3 million, an 83% increase from $11.6 million in the prior-year period, as the company highlighted continued growth in its base business, contributions from recent product relaunches, and the early rollout of its
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -58.33% and +4.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?